Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China. The companies plan to create a Sino-Canadian joint venture company based in...

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on...

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral...

Profound Medical (TSX-V:PRN) has received CE Mark approval for the commercial sale of Tulsa-Pro. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically-driven ultrasound...

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed. The double-blind, randomized Phase 2b study of 180 patients with...

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday. “We have known the story since...

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the...

In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe...

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033...

TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery. The FDA advised the company that it has not...

Avivagen (TSX-V:VIV) has reported positive results of a trial of OxC-beta Livestock as a feed additive for swine run by COFCO Nutrition and Health Research Institute (COFCO NHRI) of Beijing. The trial evaluated OxC...

Venaxis (NASDAQ:APPY), closely-held Strand Life Sciences of India and its U.S. subsidiary, Strand Genomics, have terminated a series of transactions between the companies. The termination affects an asset purchase...

Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...

The FDA has provided written feedback to Titan Pharmaceuticals (NASDAQ:TTNP) on the initial development plan for its proprietary ropinirole hydrochloride implant for Parkinson’s disease. Based on the FDA’s feedback on...

Pivotal Therapeutics (CSE:PVO; OTC PINK:PVTTF) currently is unable to repay $7.7-million of convertible notes, which came due March 4, 2016, and at least one noteholder has advised the company that it intends to...

WMUR Channel 9 in Manchester, NH has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction...

Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers. The...

Closely-held NovellusDx of Israel has appointed Heiner Dreismann and Dr. Charles Woler to the board. “The appointment of Drs. Dreismann and Woler, both venerated leaders in the biotech and pharma industries, with strong...

The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic...

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported revenue of $20-million for the final quarter of 2015, up 54% from $13-million in the year earlier quarter, and up 18% from the third quarter of 2015. Product...